Current controversies in traditional and expanded carrier screening

Current Opinion in Obstetrics and Gynecology

Volumn 28, Issue 2, 2016, Pages 136-141

  Lazarin, Gabriel A ^a   Goldberg, James D ^a  

^a Counsyl ^*  (United States)

Author keywords

expanded carrier screening; genetic counseling; Mendelian disease; prenatal genetics

Indexed keywords

CLINICAL PRACTICE; CYSTIC FIBROSIS; EDUCATION; EXPANDED CARRIER SCREENING; GENETIC COUNSELING; GENETIC SCREENING; GENETICS; HETEROZYGOTE; HUMAN; INFORMED CONSENT; LABORATORY TEST; OBSTETRICIAN; ORGANIZATION; PRIORITY JOURNAL; REVIEW; TAY SACHS DISEASE; ETHICS; GENETIC DISEASES, INBORN; PRACTICE GUIDELINE; PROCEDURES;

GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC TESTING; HETEROZYGOTE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84960330499     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000256     Document Type: Review

References (22)

1. Nazareth SB, Lazarin GA, Goldberg JD. Changing trends in carrier screening for genetic disease in the United States. Prenat Diagn 2015; 35:931-935.
2. Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine - points to consider. Obstet Gyn 2015; 125:653-662.
3. Benn P, Chapman AR, Erickson K, et al. Obstetricians' and gynecologists' practice and opinions of expanded carrier testing and noninvasive prenatal testing. Prenat Diagn 2014; 34:145-152.
4. Ram KT, Klugman SD. Best practices: antenatal screening for common genetic conditions other than aneuploidy. Curr Opin Obstet Gynecol 2010; 22:139-145.
5. Gross SJ, Pletcher BA, Monaghan KG. Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008; 10:54-56.
6. Haque IS, Lazarin GA, Raia M, et al. 'Rare' disease is common: results from 388,994 expanded carrier screens of up to 108 genes. Fert Steril 2015; 104:e65.
7. Lazarin GA, Haque IS, Nazareth S, et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med 2013; 15:178-186.
8. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med 2013; 15:482-483.
9. Elias S, Annas GJ. Generic consent for genetic screening. N Engl J Med 1994; 330:1611-1613.
10. Reeves A, Trepanier A. Comparison of informed consent preferences for multiplex genetic carrier screening among a diverse population. J Genet Couns 2015. doi: 10.1007/s10897-015-9854-4.
11. Lazarin GA, Detweiler S, Nazareth SB, Ashkinadze E. Genetic counselors' perspectives and practices regarding expanded carrier screening after initial clinical availability. J Genet Couns 2015. doi:10.1007/s10897-015-9881-1.
12. Martin J, Asan,. Yi Y, et al. Comprehensive carrier genetic test using nextgeneration deoxyribonucleic acid sequencing in infertile couples wishing to conceive through assisted reproductive technology. Fert Steril 2015; 104:1286-1293.
13. Lazarin GA, Hawthorne F, Collins NS, et al. Systematic classification of disease severity for evaluation of expanded carrier screening panels. PLoS One 2014; 9:e114391.
14. Wienke S, Brown K, Farmer M, Strange C. Expanded carrier screening - does bigger mean better? J Community Genet 2014; 5:191-198.
15. Shiroff JJ, Nemeth LS. Public perceptions of recessive carrier testing in the preconception and prenatal periods. J Obstet Gynecol Neonatal Nurs 2015; 44:717-725.
16. Perreault-Micale C, Davie J, Breton B, et al. A rigorous approach for selection of optimal variant sets for carrier screening with demonstration of clinical utility. Mol Genet Genomic Med 2015; 3:363-373.
17. Lazarin GA, Haque IS, Kang HP, Evans EA. Performance of nextgeneration sequencing versus targeted genotyping for population carrier screening; Abstract #47. Presented at the 2014 ACMG Annual Clinical Genetics Meeting, March 28, 2014, Nashville, TN.
18. Loukas YL, Thodi G, Molou E, et al. Clinical diagnostic next-generation sequencing: the case of CFTR carrier screening. Scand J Clin Lab Invest 2015; 75:374-381.
19. Lim RM, Silver AJ, Silver MJ, et al. Targeted mutation screening panels expose systematic population bias in detection of cystic fibrosis risk. Genet Med 2015. doi: 10.1038/gim.2015.52.
20. Muzzey D, Lazarin GA, Haque IS. Detection rate for prevalent diseases has greater impact than panel size on the efficacy of expanded carrier screens. Fert Steril 2015; 104:e65.
21. Matheny ME, Gandhi TK, Orav EJ, et al. Impact of an automated test results management system on patients' satisfaction about test result communication. Arch Intern Med 2007; 167:2233-2239.
22. Denne EW, Gilats M, Lazarin GA, et al. A unique service delivery model for genetic counseling services. J Genet Counsel 2015; 24:1059.